Pulmatrix(PULM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PULM Pulmatrix

Post-Mkt 03-05 18:08:58 EST

2.14

-0.02

-0.93%

High2.22	Low2.02	Vol47.70K
Open2.09	D1 Closing2.16	Amplitude9.49%
Mkt Cap7.82M	Tradable Cap7.76M	Total Shares3.65M
T/O100.20K	T/O Rate1.31%	Tradable Shares3.63M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PULM","market":"US","secType":"STK","nameCN":"Pulmatrix","latestPrice":2.14,"timestamp":1772744400000,"preClose":2.16,"halted":0,"volume":47695,"delay":0,"changeRate":-0.009259259259259267,"floatShares":3628121,"shares":3652285,"eps":-1.41,"marketStatus":"Post-Mkt","change":-0.02,"latestTime":"03-05 18:08:58 EST","open":2.09,"high":2.22,"low":2.015,"amount":100203.9812,"amplitude":0.094907,"askPrice":3.13,"askSize":100,"bidPrice":2.03,"bidSize":600,"shortable":3,"etf":0,"ttmEps":-1.41,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1772758800000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1395374400000,"exchange":"NASDAQ","adjPreClose":2.16,"preHourTrading":{"tag":"盘前","latestPrice":2.119,"preClose":2.16,"latestTime":"08:21 EST","volume":100,"amount":211.90000000000003,"timestamp":1772716911017,"change":-0.041,"changeRate":-0.018981,"amplitude":0},"volumeRatio":0.363967},"requestUrl":"/m/hq/s/PULM/tweets","defaultTab":"tweets","newsList":[{"id":"2616020356","title":"Gyre Therapeutics to Buy Cullgen, Which Ends Merger With Pulmatrix","url":"https://stock-news.laohu8.com/highlight/detail?id=2616020356","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616020356?lang=en_us&edition=fundamental","pubTime":"2026-03-02 23:23","pubTimestamp":1772464980,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics has agreed to buy privately held, clinical-stage biopharmaceutical company Cullgen in an all-stock transaction valued at about $300 million, upending plans by Pulmatrix to merge with Cullgen.Gyre on Monday said the acquisition of Cullgen will create a U.S.- and China-based fully integrated biopharmaceutical company with revenue-producing commercial assets and a pipeline of degraders, targeting inflammatory diseases and cancers.San Diego-based Gyre said it expects to complete the acquisition early in the second quarter.Pulmatrix, a Framingham, Mass., biopharmaceutical company, in late 2024 agreed to merge with China-based Cullgen, but the deal encountered regulatory delays in China, and Pulmatrix on Monday said Cullgen had terminated the agreement.Pulmatrix said it has been working to identify an alternative reverse merger opportunity, adding that it is encouraged by the interest it has received and a recent increase in deal activity within its industry.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GYRE","BK4139","PULM","BK4007"],"gpt_icon":0},{"id":"2616332424","title":"Pulmatrix Inc - Advances Discussions on Alternative Merger Opportunities","url":"https://stock-news.laohu8.com/highlight/detail?id=2616332424","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616332424?lang=en_us&edition=fundamental","pubTime":"2026-03-02 21:00","pubTimestamp":1772456405,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nTUA3W3PNB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","PULM"],"gpt_icon":0},{"id":"2616324103","title":"Press Release: Pulmatrix Announces Termination of Prior Planned Merger and Continues Pursuit of Alternative Merger Opportunities","url":"https://stock-news.laohu8.com/highlight/detail?id=2616324103","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616324103?lang=en_us&edition=fundamental","pubTime":"2026-03-02 21:00","pubTimestamp":1772456400,"startTime":"0","endTime":"0","summary":"Cullgen had been seeking approval for a merger with Pulmatrix from the China Securities Regulatory Commission and on February 28, 2026, notified Pulmatrix that Cullgen was terminating the Merger Agreement. - Pulmatrix advances existing discussions on alternative merger opportunities -. Peter Ludlum, Interim Chief Executive Officer of Pulmatrix, commented, \"Due to the significant delays at the Chinese Regulatory Authority  in 2025, we initiated a process earlier this year to identify an alternative reverse merger opportunity for the Company, and we are encouraged by both the interest we've had to date as well as the recent increase in transaction activity within our industry.\"","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4555","BK4585","BK4099","BK4588","03160","TM","BK4007","PULM","BK4604"],"gpt_icon":0},{"id":"2614044027","title":"Pulmatrix Q4 EPS $(0.25) Up From $(0.55) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2614044027","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614044027?lang=en_us&edition=fundamental","pubTime":"2026-02-26 21:19","pubTimestamp":1772111950,"startTime":"0","endTime":"0","summary":"Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(0.25) per share. This is a 54.55 percent increase over losses of $(0.55) per share from the same period last year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/02/50885693/pulmatrix-q4-eps-0-25-up-from-0-55-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PULM"],"gpt_icon":0},{"id":"2614404492","title":"Pulmatrix FY 2025 net loss USD 5.2 million -46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614404492","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614404492?lang=en_us&edition=fundamental","pubTime":"2026-02-26 21:05","pubTimestamp":1772111154,"startTime":"0","endTime":"0","summary":"Pulmatrix reported FY 2025 results with no revenue, as wind-down activities tied to its Cipla agreement for the PUR1900 program were completed in FY 2024. Net loss was USD 5.2 million in FY 2025, with R&D expense of USD 38,000 and G&A expense of USD 5.1 million. Cash and cash equivalents were USD 4.1 million as of Dec. 31, 2025, and Pulmatrix said its cash position is sufficient to fund operations into Q1 2027. On the corporate front, Pulmatrix said it is continuing efforts to license or monetize its iSPERSE technology and clinical assets, including PUR3100 , PUR1800 , and PUR1900 , for which partner Cipla completed a Phase 2 study in India and received approval to proceed to Phase 3; Pulmatrix is eligible for 2% royalties on potential future net sales by Cipla outside the U.S. Pulmatrix also provided an update on its proposed merger with Cullgen, noting stockholder approval was received in June 2025, and that the parties waived the merger agreement’s “no solicitation” clause in Decemb","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nNDLshqW3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PULM","BK4007"],"gpt_icon":0},{"id":"2614804418","title":"Press Release: Pulmatrix Announces Year-End and Fourth Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2614804418","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614804418?lang=en_us&edition=fundamental","pubTime":"2026-02-26 21:05","pubTimestamp":1772111100,"startTime":"0","endTime":"0","summary":"Plans to License or Monetize our Migraine and Inhalation Assets Continue. FRAMINGHAM, Mass., Feb. 26, 2026 /PRNewswire/ -- Pulmatrix, Inc.  , a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE technology, today announced year-end and fourth quarter financial results for 2025 and provided a corporate update.On June 16, 2025, the Company held a special meeting in lieu of the 2025 annual meeting of Pulmatrix stockholders, at which the Company's stockholders approved the Merger and related proposals. The closing of the Merger is subject to other customary closing conditions, including Nasdaq's approval of the listing of the shares of Pulmatrix common stock to be issued in connection with the Merger and approval from the CSRC.On December 17, 2025, the Company and Cullgen mutually agreed to waive the \"No Solicitation\"","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4604","BK4588","BK4007","TM","BK4585","BK4099","03160","PULM","BK4555"],"gpt_icon":0},{"id":"2592907646","title":"BRIEF-Pulmatrix And Cullgen Continue To Pursue Merger","url":"https://stock-news.laohu8.com/highlight/detail?id=2592907646","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592907646?lang=en_us&edition=fundamental","pubTime":"2025-12-18 23:02","pubTimestamp":1766070142,"startTime":"0","endTime":"0","summary":"BRIEF-Pulmatrix And Cullgen Continue To Pursue Merger Dec 18 (Reuters) - Pulmatrix Inc PULM.O:PULMATRIX AND CULLGEN CONTINUE TO PURSUE MERGER WHILE GRANTING EACH OTHER WAIVERS TO EXPLORE ALTERNATIVESP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nTUA212RRK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PULM"],"gpt_icon":0},{"id":"2592066779","title":"Pulmatrix and Cullgen Waive No-Solicitation Clause to Explore Alternatives Amid Ongoing Merger Approval Process","url":"https://stock-news.laohu8.com/highlight/detail?id=2592066779","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592066779?lang=en_us&edition=fundamental","pubTime":"2025-12-18 21:05","pubTimestamp":1766063117,"startTime":"0","endTime":"0","summary":"Pulmatrix and Cullgen have mutually agreed to waive the \"No Solicitation\" clause in their previously signed merger agreement, allowing both companies to explore alternative transactions while continuing to seek approval for their planned combination. The companies remain committed to working together toward completing the merger, which was approved by Pulmatrix stockholders in June 2025 but is still pending regulatory approval from the China Securities Regulatory Commission.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pulmatrix Inc. published the original content used to generate this news brief via PR Newswire  on December 18, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nNDL2j7jGX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PULM","BK4007"],"gpt_icon":0},{"id":"2592990666","title":"Pulmatrix and Cullgen Continue to Pursue Merger While Granting Each Other Waivers to Explore Alternatives","url":"https://stock-news.laohu8.com/highlight/detail?id=2592990666","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592990666?lang=en_us&edition=fundamental","pubTime":"2025-12-18 21:05","pubTimestamp":1766063100,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nTUA212RRK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PULM","BK4007"],"gpt_icon":0},{"id":"2592906667","title":"Pulmatrix Inc - Co and Cullgen Waive \"No Solicitation\" Clause in Merger Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2592906667","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592906667?lang=en_us&edition=fundamental","pubTime":"2025-12-18 21:05","pubTimestamp":1766063100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nTUA212RRK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PULM","BK4007"],"gpt_icon":0},{"id":"2576702308","title":"Pulmatrix Reports Q3 2025 Results and Strategic Shift","url":"https://stock-news.laohu8.com/highlight/detail?id=2576702308","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576702308?lang=en_us&edition=fundamental","pubTime":"2025-10-17 11:57","pubTimestamp":1760673476,"startTime":"0","endTime":"0","summary":"Pulmatrix ( ($PULM) ) has released its Q3 earnings. Here is a breakdown of the information Pulmatrix presented to its investors. Pulmatrix, Inc. is...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pulmatrix-reports-q3-2025-results-and-strategic-shift?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pulmatrix-reports-q3-2025-results-and-strategic-shift?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","PULM"],"gpt_icon":0},{"id":"2575746616","title":"Pulmatrix reports Q3 EPS (24c) vs. (71c) last year","url":"https://stock-news.laohu8.com/highlight/detail?id=2575746616","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575746616?lang=en_us&edition=fundamental","pubTime":"2025-10-16 20:21","pubTimestamp":1760617283,"startTime":"0","endTime":"0","summary":"Reports Q3 revenue $0 vs. $366,000 last year. Revenue decrease is primarily related to completion of the wind down of the PUR1900 Phase 2b clinical...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/pulmatrix-reports-q3-eps-24c-vs-71c-last-year-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/pulmatrix-reports-q3-eps-24c-vs-71c-last-year-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PULM"],"gpt_icon":0},{"id":"2575745037","title":"Biopharma Pulmatrix's Q3 revenue drops to $0 as trial ends, plans asset divestment","url":"https://stock-news.laohu8.com/highlight/detail?id=2575745037","media":"Reuters","labels":["dataReport","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575745037?lang=en_us&edition=fundamental","pubTime":"2025-10-16 20:16","pubTimestamp":1760616971,"startTime":"0","endTime":"0","summary":"Biopharma Pulmatrix's Q3 revenue drops to $0 as trial ends, plans asset divestmentOverviewPulmatrix Q3 2025 revenue decreased to $0, primarily due to winding down PUR1900 clinical trialCompany plans t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nL2N3VX0EB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"Biopharma Pulmatrix's Q3 revenue drops to $0 as trial ends, plans asset divestment","news_tag":"dataReport,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PULM","BK4007"],"gpt_icon":0},{"id":"2575374572","title":"Pulmatrix Q3 EPS $(0.24) Up From $(0.71) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2575374572","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575374572?lang=en_us&edition=fundamental","pubTime":"2025-10-16 20:14","pubTimestamp":1760616841,"startTime":"0","endTime":"0","summary":"Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(0.24) per share. This is a 66.2 percent increase over losses of $(0.71) per share from the same period last year.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/10/48246954/pulmatrix-q3-eps-0-24-up-from-0-71-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PULM"],"gpt_icon":0},{"id":"2575674515","title":"BRIEF-Pulmatrix Q3 EPS USD -0.24","url":"https://stock-news.laohu8.com/highlight/detail?id=2575674515","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575674515?lang=en_us&edition=fundamental","pubTime":"2025-10-16 20:05","pubTimestamp":1760616354,"startTime":"0","endTime":"0","summary":"BRIEF-Pulmatrix Q3 EPS USD -0.24\n\n\nOct 16 (Reuters) - Pulmatrix Q3 operating expenses USD 866 thousand.\n\nQ3 income from operations USD -866 thousand\nQ3 net income USD -877 thousand","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nPLX8C43DE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PULM"],"gpt_icon":0},{"id":"2575745153","title":"Pulmatrix Shareholders Approve Merger with Cullgen; Company Moves to Divest iSPERSE™ Technology and Migraine Assets","url":"https://stock-news.laohu8.com/highlight/detail?id=2575745153","media":"Reuters","labels":["corporation","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575745153?lang=en_us&edition=fundamental","pubTime":"2025-10-16 20:05","pubTimestamp":1760616334,"startTime":"0","endTime":"0","summary":"Pulmatrix Inc. provided an update on its proposed merger with Cullgen, a privately held, clinical-stage biopharmaceutical company focused on targeted protein degrader therapies for pain, cancer, and other diseases. The merger, if completed, would result in a Nasdaq-listed company featuring three degrader programs in Phase 1 clinical trials-two for cancer and one for acute and chronic pain, for which Cullgen recently completed enrollment. Pulmatrix is also in the process of potentially divesting its patent portfolio, including its proprietary iSPERSE inhalation technology and related clinical programs, such as its Phase 2 ready acute migraine program. The merger was approved by Pulmatrix stockholders at a special meeting on June 16, 2025, and remains subject to customary closing conditions. If finalized, Cullgen's business will continue as the business of the combined company.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nNDLtlvnT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Pulmatrix Shareholders Approve Merger with Cullgen; Company Moves to Divest iSPERSE™ Technology and Migraine Assets","news_tag":"corporation,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PULM","BK4007"],"gpt_icon":0},{"id":"2575745901","title":"Pulmatrix Q3 Operating Expenses USD 866 Thousand","url":"https://stock-news.laohu8.com/highlight/detail?id=2575745901","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575745901?lang=en_us&edition=fundamental","pubTime":"2025-10-16 20:05","pubTimestamp":1760616309,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nPLX8C43DE:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PULM","BK4007"],"gpt_icon":0},{"id":"2575459047","title":"Pulmatrix Announces Third Quarter 2025 Financial Results and Divestment Plan for Migraine and Inhalation Assets","url":"https://stock-news.laohu8.com/highlight/detail?id=2575459047","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575459047?lang=en_us&edition=fundamental","pubTime":"2025-10-16 20:05","pubTimestamp":1760616308,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nTUA7PKWWF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PULM","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pulmatrix.com","stockEarnings":[{"period":"1week","weight":-0.3271},{"period":"1month","weight":-0.166},{"period":"3month","weight":-0.4941},{"period":"6month","weight":-0.5565},{"period":"1year","weight":-0.6975},{"period":"ytd","weight":-0.0314}],"compareEarnings":[{"period":"1week","weight":-0.0116},{"period":"1month","weight":-0.0148},{"period":"3month","weight":0.0011},{"period":"6month","weight":0.0585},{"period":"1year","weight":0.1877},{"period":"ytd","weight":0.0047}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.296748},{"month":2,"riseRate":0.5,"avgChangeRate":0.041046},{"month":3,"riseRate":0.25,"avgChangeRate":-0.147902},{"month":4,"riseRate":0.416667,"avgChangeRate":-0.040652},{"month":5,"riseRate":0.416667,"avgChangeRate":0.027152},{"month":6,"riseRate":0.25,"avgChangeRate":-0.0597},{"month":7,"riseRate":0.25,"avgChangeRate":-0.076292},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.103916},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.033052},{"month":10,"riseRate":0.416667,"avgChangeRate":-0.061729},{"month":11,"riseRate":0.416667,"avgChangeRate":0.146297},{"month":12,"riseRate":0.25,"avgChangeRate":-0.143561}],"exchange":"NASDAQ","name":"Pulmatrix","nameEN":"Pulmatrix"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Pulmatrix(PULM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Pulmatrix(PULM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Pulmatrix,PULM,Pulmatrix股票,Pulmatrix股票老虎,Pulmatrix股票老虎国际,Pulmatrix行情,Pulmatrix股票行情,Pulmatrix股价,Pulmatrix股市,Pulmatrix股票价格,Pulmatrix股票交易,Pulmatrix股票购买,Pulmatrix股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Pulmatrix(PULM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Pulmatrix(PULM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction